Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program
- Friday, May 21, 2021, 7:16
- Environment
- Add a comment
SAN DIEGO, May 21, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced an incremental update from the first cohort of…
About the Author
adminasapcorp has written 41552 stories on this site.